VIVUS, Inc. (VVUS) Qsymia Prescriptions Show Gains During Slow Holiday Week (ARNA) (OREX)

Article Related Press Releases (1) Related Articles (4) Stock Quotes (3) Comments (0)

VIVUS, Inc. (Nasdaq: VVUS) is lower on the session amid new data for prescriptions of its weight-loss pill, Qsymia.

According to Bloomberg Industries, Qsymia prescriptions rose 24 percent to 2,859 last week. Data comes from Symphony Health Solutions.

Bloomberg also noted that the shortened holiday week (MLK Day) saw its retail prescription index fall nine percent.

The news comes as peer Arena Pharma (Nasdaq: ARNA) and its partner Eisai are planning to debut competing obesity pill Belviq soon. Orexigen (Nasdaq: OREX), which is developing Contrave as a weight-loss pill, is still in testing phases.

VIVUS is off about 0.4 percent Monday morning.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• VIVUS (VVUS) Qsymia Prescriptions Fall Ahead of Belviq Launch (ARNA)
• Amarin (AMRN) NCE Delay Not all Negative - MKM Partners
• Nokia (NOK) Could See Downside as Siemens Exits NSN Joint-Venture - Goldman

Create E-mail Alert Related Categories

Analyst Comments, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?